CLIC4, ERp29, and Smac/DIABLO derived from metastatic cancer stem-like cells stratify prognostic risks of colorectal cancer

Clinical Cancer Research

Volumn 20, Issue 14, 2014, Pages 3809-3817

  Deng, Yong Jian ^a,b   Tang, Na ^a,e   Liu, Chao ^a,b   Zhang, Jiang Yu ^a,c   An, Sheng Li ^a   Peng, Yin Li ^a   Ma, Li Li ^a   Li, Guang Qiu ^a   Jiang, Qiang ^a   Hu, Chun Ting ^a   Wang, Ya Nan ^a   Liang, Yao Ze ^a   Bian, Xiu Wu ^d   Fang, Wei Gang ^f   Ding, Yan Qing ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Department of Pathology School of Basic Medical Sciences Southern Medical University ^*  (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e SHENZHEN PEOPLE'S HOSPITAL   (China)

^f PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE INTRACELLULAR CHANNEL 4; ENDOPLASMIC RETICULUM PROTEIN 29; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR MARKER; UNCLASSIFIED DRUG; CHLORIDE CHANNEL; CLIC4 PROTEIN, HUMAN; DIABLO PROTEIN, HUMAN; ERP29 PROTEIN, HUMAN; HEAT SHOCK PROTEIN; MITOCHONDRIAL PROTEIN; SIGNAL PEPTIDE;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC CANCER STEM LIKE CELL; PATIENT IDENTIFICATION; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; VALIDATION PROCESS; VERY ELDERLY; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RISK; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHLORIDE CHANNELS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; MULTIVARIATE ANALYSIS; NEOPLASTIC STEM CELLS; PROGNOSIS; RISK; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84904396623     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1887     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41.
3. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010;28:4417-24.
4. Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, et al. Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. J Clin Oncol 2011;29:4516-25.
5. Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009;27:4701-8.
6. Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst 2007;99:858-67.
7. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29:17-24.
8. Fakih MM. KRAS mutation screening in colorectal cancer: From paper to practice. Clin Colorectal Cancer 2010;9:22-30.
9. Perez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Paya A, Brea A, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 2012;61:865-72.
10. Gellad Z. Personalisation of colorectal cancer screening. Lancet Oncol 2013;14:673-5.
11. Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007;17:3-14. (Pubitemid 46096419)
12. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-23. (Pubitemid 47355323)
13. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26:3015-24.
14. Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010;6:603-15.
15. Ueno H, Mochizuki H, Akagi Y, Kusumi T, Yamada K, Ikegami M, et al. Optimal colorectal cancer staging criteria in TNM classification. J Clin Oncol 2012;30:1519-26.
16. Tsai WS, Hsieh PS, Yeh CY, Chiang JM, Tang R, Chen JS, et al. Impact of chemotherapy-related prognostic factors on long-term survival in patients with stage III colorectal cancer after curative resection. Int J Clin Oncol 2013;18:242-53.
17. Wu X, Zhang J, He X, Wang C, Lian L, Liu H, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. J Gastrointest Surg 2012;16:646-55.
18. Benson AB III. Adjuvant chemotherapy for stage II and III colorectal cancer. Clin Adv Hematol Oncol 2011;9:616-8.
19. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012;104:1635-46.
20. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10. (Pubitemid 46067310)
21. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5. (Pubitemid 46067311)
22. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007;104:10158-63. (Pubitemid 47175279)
23. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111-20.
24. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010;103:382-90.
25. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol 2011;223:147-61.
26. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-9.
27. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distributionwithin intrinsic molecular subtype. J Clin Pathol 2011;64:937-46.
28. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8. (Pubitemid 36418143)
29. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-67. (Pubitemid 350056407)
30. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-13.
31. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744-9. (Pubitemid 41486367)
32. Li G, Liu C, Yuan J, Xiao X, Tang N, Hao J, et al. CD133(+) single cell-derived progenies of colorectal cancer cell line SW480 with different invasive and metastatic potential. Clin Exp Metastasis 2010;27:517-27.
33. Suh KS, Crutchley JM, Koochek A, Ryscavage A, Bhat K, Tanaka T, et al. Reciprocal modifications of CLIC4 in tumor epithelium and stroma mark malignant progression of multiple human cancers. Clin Cancer Res 2007;13:121-31. (Pubitemid 46121860)
34. Shnyder SD, Mangum JE, Hubbard MJ. Triplex profiling of functionally distinct chaperones (ERp29/PDI/BiP) reveals marked heterogeneity of the endoplasmic reticulum proteome in cancer. J Proteome Res 2008;7:3364-72.
35. Bambang IF, Xu S, Zhou J, Salto-Tellez M, Sethi SK, Zhang D. Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells. Lab Invest 2009;89:1229-42.
36. Mizutani Y, Katsuoka Y, Bonavida B. Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer. Int J Oncol 2012;40:1246-50.
37. Pluta P, Cebula-Obrzut B, Ehemann V, Pluta A, Wierzbowska A, Piekarski J, et al. Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma 2011;58:430-5.
38. Chen B-D, Xu A-G, Yu Z-J, Zhang X-H, Xu Y-C, Zhong X-F, et al. Comparison of clinical features with colorectal cancer in four areas from Guangdong Province. J Pract Med 2010;26:1643-5.
39. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003-7. (Pubitemid 350014593)
40. Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013;493:106-10.
41. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010;16:876-87.
42. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
43. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS MED 2010;7:e1000279.
44. Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, et al. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res 2011;17:1490-501.
45. Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S, et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A 2009;106:19035-9.
46. Quint K, Tonigold M, Di Fazio P, Montalbano R, Lingelbach S, Ruckert F, et al. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. Int J Oncol 2012;41:2093-102.
47. Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z, et al. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene 2011;30:4707-20.